Mannkind Corp (MNKD) 7.09 $MNKD
MNKD, DEPO, RWR, NTES, TTM, PAY Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Aug 18, 7:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mannkind Corp (NASDAQ:MNKD), Depomed Inc (NASDAQ
EPO), Dj Wilshire Reit Etf (NYSE:RWR), NetEase.com Inc (NASDAQ:NTES), Tata Motors Ltd (NYSE:TTM), VeriFone Systems Inc (NYSE
AY) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Ebola Vaccine and Inhaled Insulin Incoming
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Aug 16, 5:01AM CDT
In this healthcare-focused of episode of Where The Money Is, analysts David Williamson and Michael Douglass tackle the weeks biggest stories in pharma and biotech, and how the industry is attempting to combat the Ebola Outbreak. MannKind's big news...
MannKind Falls 2.70% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Aug 15, 4:32PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.66 to a high of $7.11. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $7.00 on volume of 16.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna
PR Newswire - Thu Aug 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), MannKind Corp. (NASDAQ: MNKD), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline PLC (NYSE: GSK) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5727-100free.
5 Things MannKind Corp.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 13, 5:30PM CDT
MannKind recently signed a marketing partnership with Sanofi and later in the day held a second conference call to discuss its second-quarter earnings. Here are five quotes from MannKind's management with details on the future of the company and...
Blame MannKind's Fall on its Bloated Balance Sheet
at The Street - Wed Aug 13, 11:04AM CDT
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.
Uptrend Call Working As MannKind Stock Rises 0.6% (MNKD)
Comtex SmarTrend(R) - Tue Aug 12, 11:11AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 0.60% as of today's recent price of $7.50.
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents
eResearch Highlights NASDAQ Volume Leaders for Monday, August 11
ACCESSWIRE - Tue Aug 12, 9:02AM CDT
TORONTO, ON / ACCESSWIRE / August 12, 2014 / eResearch Corporation collaborates with theUpTrend.com in providing technical charts and opinions on the previous day's largest share volume leaders for each of the three major North American stock exchanges (on a rotating daily basis).
Critical Alerts For MannKind, Kinder Morgan, Kohls, Maxim Integrated Products and United Technologies. Released By InvestorsObserver
PR Newswire - Tue Aug 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, KMI, KSS, MXIM and UTX.
MannKind Corporation Stock Signs Up Sanofi, Investors Conflicted
Brian Orelli, The Motley Fool - Motley Fool - Tue Aug 12, 6:00AM CDT
After years of discussions, MannKind finally has a partner for its inhaled insulin Afrezza. And a pretty good one at that. Source: MannKind The biotech announced a deal with diabetes expert Sanofi yesterday. There are two ways of...
MannKind Enters into a Global Deal with Sanofi for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 4:20PM CDT
MannKind (MNKD) has a inked a deal with Sanofi (SNY) on Afrezza.
Look for Shares of MannKind to Potentially Pullback after Yesterday's 4.92% Rise
Comtex SmarTrend(R) - Mon Aug 11, 3:50PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $8.31 to a high of $10.08. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $8.30 on volume of 62.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
4 Big Stocks to Trade (or Not)
at The Street - Mon Aug 11, 2:13PM CDT
Here's a look at how to trade some of the most active stocks on the market today.
Sanofi partners with MannKind for Afrezza (insulin human) Rapid-Acting Inhaled Insulin
M2 - Mon Aug 11, 11:06AM CDT
Therapeutic solution company Sanofi (EURONEXT:SAN)(NYSE:SNY) on Monday reported a worldwide exclusive licensing agreement for development and commercialisation of Afrezza (insulin human) Inhalation Powder in partnership with MannKind (NasdaqGM:MNKD).
Jim Cramer's Mad Dash: Good News for Tesla and MannKind
at The Street - Mon Aug 11, 10:48AM CDT
TheStreet's Jim Cramer takes a look at what's pushing shares of Tesla Motors and MannKind higher on Monday.
Stocks Higher, Nasdaq Leads; Kinder Morgan, Priceline Rising
at Investor's Business Daily - Mon Aug 11, 9:31AM CDT
A rally in global markets and positive investor reaction to one of the energy industry's largest proposed merger deals helped send stocks higher early Monday. The Nasdaq jumped 0.6%, led by Tesla Motor's (TSLA) 5% gain. The S&P 500 climbed 0.5% and...
MannKind Corporation Reports 2014 Second Quarter Financial Results
GlobeNewswire - Mon Aug 11, 8:59AM CDT
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2014.
Why ManKind (MNKD) Stock Is Soaring Today
at The Street - Mon Aug 11, 7:20AM CDT
Sanofi (SNY) agreed to pay the biopharmaceutical company up to $925 million for global rights to the world’s only available inhaled insulin.
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin
PR Newswire - Mon Aug 11, 6:00AM CDT
Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015.
MNKD, DEPO, RWR, NTES, TTM, PAY Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Aug 18, 7:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mannkind Corp (NASDAQ:MNKD), Depomed Inc (NASDAQ
EPO), Dj Wilshire Reit Etf (NYSE:RWR), NetEase.com Inc (NASDAQ:NTES), Tata Motors Ltd (NYSE:TTM), VeriFone Systems Inc (NYSE AY) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: Ebola Vaccine and Inhaled Insulin Incoming
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Aug 16, 5:01AM CDT
In this healthcare-focused of episode of Where The Money Is, analysts David Williamson and Michael Douglass tackle the weeks biggest stories in pharma and biotech, and how the industry is attempting to combat the Ebola Outbreak. MannKind's big news...
MannKind Falls 2.70% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Aug 15, 4:32PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.66 to a high of $7.11. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $7.00 on volume of 16.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna
PR Newswire - Thu Aug 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), MannKind Corp. (NASDAQ: MNKD), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline PLC (NYSE: GSK) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5727-100free.
5 Things MannKind Corp.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 13, 5:30PM CDT
MannKind recently signed a marketing partnership with Sanofi and later in the day held a second conference call to discuss its second-quarter earnings. Here are five quotes from MannKind's management with details on the future of the company and...
Blame MannKind's Fall on its Bloated Balance Sheet
at The Street - Wed Aug 13, 11:04AM CDT
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.
Uptrend Call Working As MannKind Stock Rises 0.6% (MNKD)
Comtex SmarTrend(R) - Tue Aug 12, 11:11AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 0.60% as of today's recent price of $7.50.
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents
eResearch Highlights NASDAQ Volume Leaders for Monday, August 11
ACCESSWIRE - Tue Aug 12, 9:02AM CDT
TORONTO, ON / ACCESSWIRE / August 12, 2014 / eResearch Corporation collaborates with theUpTrend.com in providing technical charts and opinions on the previous day's largest share volume leaders for each of the three major North American stock exchanges (on a rotating daily basis).
Critical Alerts For MannKind, Kinder Morgan, Kohls, Maxim Integrated Products and United Technologies. Released By InvestorsObserver
PR Newswire - Tue Aug 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, KMI, KSS, MXIM and UTX.
MannKind Corporation Stock Signs Up Sanofi, Investors Conflicted
Brian Orelli, The Motley Fool - Motley Fool - Tue Aug 12, 6:00AM CDT
After years of discussions, MannKind finally has a partner for its inhaled insulin Afrezza. And a pretty good one at that. Source: MannKind The biotech announced a deal with diabetes expert Sanofi yesterday. There are two ways of...
MannKind Enters into a Global Deal with Sanofi for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 4:20PM CDT
MannKind (MNKD) has a inked a deal with Sanofi (SNY) on Afrezza.
Look for Shares of MannKind to Potentially Pullback after Yesterday's 4.92% Rise
Comtex SmarTrend(R) - Mon Aug 11, 3:50PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $8.31 to a high of $10.08. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $8.30 on volume of 62.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
4 Big Stocks to Trade (or Not)
at The Street - Mon Aug 11, 2:13PM CDT
Here's a look at how to trade some of the most active stocks on the market today.
Sanofi partners with MannKind for Afrezza (insulin human) Rapid-Acting Inhaled Insulin
M2 - Mon Aug 11, 11:06AM CDT
Therapeutic solution company Sanofi (EURONEXT:SAN)(NYSE:SNY) on Monday reported a worldwide exclusive licensing agreement for development and commercialisation of Afrezza (insulin human) Inhalation Powder in partnership with MannKind (NasdaqGM:MNKD).
Jim Cramer's Mad Dash: Good News for Tesla and MannKind
at The Street - Mon Aug 11, 10:48AM CDT
TheStreet's Jim Cramer takes a look at what's pushing shares of Tesla Motors and MannKind higher on Monday.
Stocks Higher, Nasdaq Leads; Kinder Morgan, Priceline Rising
at Investor's Business Daily - Mon Aug 11, 9:31AM CDT
A rally in global markets and positive investor reaction to one of the energy industry's largest proposed merger deals helped send stocks higher early Monday. The Nasdaq jumped 0.6%, led by Tesla Motor's (TSLA) 5% gain. The S&P 500 climbed 0.5% and...
MannKind Corporation Reports 2014 Second Quarter Financial Results
GlobeNewswire - Mon Aug 11, 8:59AM CDT
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2014.
Why ManKind (MNKD) Stock Is Soaring Today
at The Street - Mon Aug 11, 7:20AM CDT
Sanofi (SNY) agreed to pay the biopharmaceutical company up to $925 million for global rights to the world’s only available inhaled insulin.
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin
PR Newswire - Mon Aug 11, 6:00AM CDT
Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015.
